- Motley Fool•9 days ago
A complete absence of data showing the potential of genetically engineered mosquitoes to benefit public health is no longer the case. However, it may take a few more years before Intrexon investors see significant contributions to the top and bottom line.
- Capital Cube•12 days ago
Click here to see latest analysisCapitalcube gives Intrexon Corp. a score of 59.Our analysis is based on comparing Intrexon Corp. with the following peers – ZIOPHARM Oncology, Inc., Eli Lilly and Company, Thermo Fisher Scientific Inc., Odyssey Marine Exploration, Inc., Fibrocell Science, Inc. and Synthetic Biologics, Inc. (ZIOP-US, LLY-US, TMO-US, OMEX-US, FCSC-US and SYN-US).Investment OutlookIntrexon […] (Read more...) The post Intrexon Corp. – Value Analysis (NYSE:XON) : July 18, 2016 appeared first on CapitalCube.
After hours: 25.330.00 (0.00%) as of 7:02 PM EDT
|Bid||25.21 x 100|
|Ask||25.40 x 3000|
|52wk Range||18.52 - 69.45|
|Day's Range||24.45 - 25.63|
|Avg Vol (3m)||1,640,941|
As of 4:02 PM EDT. Market closed.